The arrival of oral prescription weight-loss medications could have an unexpected beneficiary: the airline industry.
This month marked the availability of the first oral GLP-1 weight-loss drug, Novo Nordisk’s Wegovy pill, while Eli Lilly has said it is optimistic its oral version of Zepbound could receive US regulatory approval as early as the second quarter. Analysts say the shift from injectable treatments to pills could significantly expand usage of the drugs, with knock-on effects well beyond healthcare.
Injectable weight-loss medications have already reduced the number of obese adults in the US by an estimated 7.6 million since 2022, according to Jefferies. About 12.4% of US adults now report taking drugs in the GLP-1 class, a figure expected to rise as oral options become more widely available.
For airlines, fewer overweight passengers translate directly into lighter aircraft and improved fuel efficiency. Fuel is one of the industry’s largest expenses, and carriers have long focused on marginal weight reductions to cut costs.
Jefferies noted that airlines routinely make small operational changes to reduce onboard weight, from carrying less potable water to switching to lighter service items. In 2018, for example, United Airlines began using lighter paper for its in-flight magazine, shaving about an ounce from each copy. The change saved an estimated 170,000 gallons of fuel annually, delivering roughly $290,000 in cost savings.
The potential impact from lighter passenger payloads is far more substantial. Jefferies estimated that if the average weight of a passenger on a Boeing 737 Max 8 fell by 10% from 180 pounds, the total passenger weight on a two-cabin aircraft would drop by about 3,200 pounds. That represents roughly 2% of the plane’s maximum takeoff weight.
Such a reduction could improve fuel efficiency by approximately 1.5%, Jefferies said. The firm forecasts combined fuel costs this year of $38.6 billion across Delta Air Lines, American Airlines, United and Southwest Airlines, accounting for 19.1% of their total expenses. A 1.5% efficiency gain would equate to about $579 million in annual savings.
“Please note savings are before any lost snack sales,” Jefferies analysts joked in their note.
While the primary impact of GLP-1 medications remains firmly in healthcare and consumer markets, analysts suggest their indirect effects could ripple across multiple industries. For airlines grappling with persistently high fuel costs, even modest changes in passenger weight could translate into meaningful financial gains.
